In this issue: 2G uest Editorial Aortas, open surgical skills and gratitude 8V ascular training APDVS says goodbye to two longtime leaders during annual spring meeting
MAY 2024 Volume 20 Number 5
THE OFFICIAL NEWSPAPER OF THE
15 V AM 2024 ‘I’m a big fan of firsts’: National DEI speaker set for new meeting staple 17 Leadership SVS figures host international session to tackle cross-specialty dialogue www.vascularspecialistonline.com
PAD
Questions linger: BASIL-3 does not find for drug-eluting technologies in CLTI By Jocelyn Hudson
‘WE NEED TO CONTINUE TO BE DELIBERATE’: DEDICATED SOCIETY FOR WOMEN VASCULAR SURGEONS FORMED The inaugural president spoke to Vascular Specialist about the newly formed International Society for Women Vascular Surgeons ahead of this year’s Women’s Vascular Summit (May 3–4) in Chicago, outlining its genesis and goals, as well as some of the highlights of this year’s gathering. Linda Harris, MD, a professor of surgery and chief of vascular surgery at the University at Buffalo in Buffalo, New York, notes that she created the Women’s Vascular Summit back in 2019 and, more recently, the International Society for Women Vascular Surgeons, for two reasons: to address vascular
See page 5
I
n the UK National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA)-funded BASIL-3 randomized controlled trial (RCT), neither drug-coated balloon (DCB) angioplasty with or without bare metal stent nor drug-eluting stent (DES), when used in the femoropopliteal segment, conferred a hypothesized clinical benefit over femoropopliteal plain balloon angioplasty with or without bare metal stent. In addition, it was found that DCB with or without bare metal stent is unlikely to be cost-effective at the UK National Health Service (NHS) National Institute for Health
and Care Excellence (NICE) willingness-topay threshold. DES, on the other hand, is potentially cost-effective at this threshold. Andrew Bradbury, MD, professor of vascular surgery at the University of Birmingham in Solihull, England, and the BASIL-3 team of triallists shared this and other key findings during the 2024 Charing Cross (CX) International Symposium in London (April 23–25), addressing the question of which endovascular strategy is best in the femoropopliteal segment. The investigators presented—for the first time—results of this only completed, fully publicly funded RCT in the space.
“This was a pragmatic, ‘real-world’ UK trial whose outcomes are likely to be a realistic representation of what can be reasonably achieved across the NHS,” Bradbury said. University of Birmingham statistician Catherine Moakes, MS, reported clinical results of BASIL-3. Between Jan. 29, 2016, and Aug. 26, 2021, the trial enrolled 481 patients, with 160 randomized to plain balloon angioplasty with or without bare metal stent, 161 to DCB with or without bare metal stent, and 160 to DES.
See page 5
SVS UNVEILS TWO WOMEN VASCULAR SURGEON CANDIDATES FOR 2024–25 VICE PRESIDENT The Society for Vascular Surgery (SVS) has announced Linda Harris, MD, and Palma Shaw, MD, as the candidates for the upcoming election for SVS vice president. “This is an exciting year,” said SVS Nominating Committee Chair Ronald L. Dalman, MD,
See page 8
Vascular Specialist 9400 W. Higgins Road, Suite 315 Rosemont, IL 60018
IM
PAID
CHANGE SERVICE REQUESTED
PRESORTED STANDARD MAIL U.S. POSTAGE